International Journal of Medical Ophthalmology

International Journal of Medical Ophthalmology

2019, Vol. 1 Issue 1, Part A
Clinical spectrum in congenital nasal duct obstruction
Author(s): Dr. Rakesh Kumar, Dr. Priya Sinha and Dr. Deepak Lakra
Abstract:
Azithromycin is an azalide that acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis. Azithromycin is also noted by anti-inflammatory and immunomodulatory activity. AzaSite® (Inspire Pharmaceuticals, Inc, Durham, NC) is azithromycin ophthalmic solution, 1% formulated in polycarbophil (the aqueous mucoadhesive polymer contained in DuraSite®) that delivers high and prolonged azithromycin concentrations in a variety of ocular tissues, including the conjunctiva, cornea and particularly the eyelid. AzaSite was approved by the Food and Drug Administration (FDA) in the US in 2007, for the treatment of bacterial conjunctivitis caused by susceptible isolates. This article aims to evaluate the peer-reviewed published scientific literature and to define well established uses of AzaSite eye drops in the field of ocular infections.
Pages: 10-11  |  581 Views  170 Downloads
Download Full Article: Click Here
How to cite this article:
Dr. Rakesh Kumar, Dr. Priya Sinha, Dr. Deepak Lakra. Clinical spectrum in congenital nasal duct obstruction. Int J Med Ophthalmol 2019;1(1):10-11. DOI: 10.33545/26638266.2019.v1.i1a.3
International Journal of Medical Ophthalmology